Citation Impact
Citing Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
2000 Standout
Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients
2001 Standout
Hyperplasia and Carcinomas in Pten-Deficient Mice and Reduced PTEN Protein in Human Bladder Cancer Patients
2006 StandoutNobel
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
1998 Standout
Cancer treatment and survivorship statistics, 2022
2022 Standout
Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress
2003
A view on drug resistance in cancer
2019 StandoutNature
High-dose methotrexate for non-AIDS primary central nervous system lymphoma
1989
Photodynamic Therapy
1998 Standout
Differing Interpretations by Pathologists of the pT Category and Grade of Transitional Cell Cancer of the Bladder
1988
Urothelial Carcinoma Associated with the Use of a Chinese Herb (Aristolochia fangchi)
2000 Standout
Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06.
1996
HIF-Dependent Antitumorigenic Effect of Antioxidants In Vivo
2007 StandoutNobel
Paraneoplastic Syndromes Involving the Nervous System
2003 Standout
The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder
1990
Guillain-Barré syndrome
2016 Standout
Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer
1999
Coordinated regulation of myeloid cells by tumours
2012 Standout
Transurethral Resection and Surveillance of Bladder Cancer Supported by 5-Aminolevulinic Acid-Induced Fluorescence Endoscopy
1999
Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma
1995 Standout
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
2002 Standout
Colorectal cancer
2013 Standout
Myeloid-derived suppressor cells as regulators of the immune system
2009 Standout
Toxicity in head and neck cancer: a review of trends and issues
2000
Muscularis mucosa differentiates two populations with different prognosis in Stage T1 bladder cancer
1995
Celiac Disease
2007 Standout
Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid
1994
Richter syndrome
2004
Toxicity profile of dexrazoxane (zinecardR, icrf-187, adr-529, nsc-169780), a modulator of doxorubicin cardiotoxicity
1991
Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses
2003
Relationship of Cytokeratin 20 and CD44 Protein Expression with WHO/ISUP Grade in pTa and pT1 Papillary Urothelial Neoplasia
2000
Bladder cancer
2016 Standout
A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
1992
Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function.
1991
The World Health Organization/International Society of Urological Pathology Consensus Classification of Urothelial (Transitional Cell) Neoplasms of the Urinary Bladder
1998 Standout
Cancer treatment and survivorship statistics, 2012
2012 Standout
Prognostic significance of atypical papillary urothelial hyperplasia
2002
Inflammation and cancer: back to Virchow?
2001 Standout
Significance of invasion to the muscularis mucosae on the progression of superficial bladder cancer
1994
Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
2003 Standout
Initial Evaluation and Response Criteria for Patients with Superficial Bladder Cancer
1990
Three‐year Follow‐up of Bladder Tumours found on Screening
1993
Urothelial Transitional Cell Carcinoma with Endophytic Growth Patterns
1997
MicroRNA signatures in human cancers
2006 Standout
Primary brain tumours in adults
2012 Standout
Adjuvant and neoadjuvant chemotherapy for invasive bladder cancer
2000
Primary central nervous system lymphoma
1988
Accumulated allelic losses in the development of invasive urothelial cancer
1993 StandoutNobel
Bladder cancer: Epidemiology, staging and grading, and diagnosis
2005 Standout
MHC antigens and tumor escape from immune surveillance
2001
Doxorubicin-Induced Cardiomyopathy
1998 Standout
Should pT1 Transitional Cell Cancers of the Bladder still be Classified as Superficial?
1988
Proteomics to study genes and genomes
2000 StandoutNature
Histologic grading of urothelial carcinoma: a reappraisal
2012
Interpretation of Biopsies of “Normal” Urothelium in Patients with Superficial Bladder Cancer
1991
Brain Tumors
2001 Standout
Head and Neck Cancer
2001 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Cancer of the Ovary
2004 Standout
A comprehensive protein ressource for the study of bladder cancer: http://biobase.dk/cgi-bin/celis
1999
In vivoblockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance
1999 StandoutNobel
METASTATIC BLADDER CANCER
1992
Recurrence, Progression and Survival in Bladder Cancer
1987
Radical Cystectomy for Stages TA, TIS and T1 Transitional Cell Carcinoma of the Bladder
1994
The clinical significance of the morphological subdivision of diffuse "histiocytic" lymphoma: a study of 162 patients treated by the Southwest Oncology Group
1982
CONTROLLED TRIAL OF PREDNISOLONE IN ACUTE POLYNEUROPATHY
1978 Standout
Telomerase activity, cell proliferation, and cancer
1998 StandoutNobel
Revised Response Criteria for Malignant Lymphoma
2007 Standout
8 Malignant lymphoma in the elderly
1987
Recurrence of high‐risk bladder cancer: A population‐based analysis
2013
Molecular analysis of a chromosomal translocation, t(9;14)(p13;q32), in a diffuse large-cell lymphoma cell line expressing the Ki-1 antigen.
1990 StandoutNobel
Bladder Cancer
2020 Standout
Two molecular pathways to transitional cell carcinoma of the bladder.
1994
Clinical Features of Hypersensitivity Reactions to Carboplatin
1999
Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients.
2001
Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience.
1986
Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)
1988
Pancytopenia and Leukemia in Hodgkin’s Disease: Report of Three Cases
1973 StandoutNobel
Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high- risk" disease?
1994
Residual Tumor Discovered in Routine Second Transurethral Resection in Patients with Stage T1 Transitional Cell Carcinoma of the Bladder
1991
Benign and low-grade papillary lesions of the urinary bladder: a review of the papilloma-papillary carcinoma controversy, and a report of five typical papillomas.
1989
Role of fluorine‐18 fluoro‐deoxyglucose positron emission tomography scan in the evaluation and follow‐up of patients with low‐grade lymphomas
2006
Cancer treatment and survivorship statistics, 2016
2016 Standout
Activation of stratospheric chlorine by reactions in liquid sulphuric acid
1994 StandoutNobel
Bladder tumours detected on screening: results at 7 years
1998
Cancer treatment and survivorship statistics, 2019
2019 Standout
Defining and Treating the Spectrum of Intermediate Risk Nonmuscle Invasive Bladder Cancer
2014
Nonlymphomatous Malignant Tumors Complicating Hodgkin's Disease
1972
Prolonged Disease-Free Survival after Autologous Bone Marrow Transplantation in Patients with Non-Hodgkin's Lymphoma with a Poor Prognosis
1987
Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization
2010 Standout
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
2015 Standout
World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997
1999 Standout
Follicular lymphoma: prognostic factors for response and survival.
1986
Marrow transplantation for acute nonlymphocytic leukemia following therapy for Hodgkin's disease.
1987 StandoutNobel
The Role of Adjuvant Chemotherapy Following Cystectomy for Invasive Bladder Cancer: A Prospective Comparative Trial
1991
Alterations in Signal Transduction Molecules in T Lymphocytes from Tumor-Bearing Mice
1992 Science
Curability of Advanced Hodgkin's Disease with Chemotherapy
1980
Defective Regulation of Inflammatory Mediators in Hodgkin's Disease
1974
Detection of Telomerase Activity in Exfoliated Cells in Urine From Patients With Bladder Cancer
1997
Enteropathy-Type Intestinal T-Cell Lymphoma: Clinical Features and Treatment of 31 Patients in a Single Center
2000
PATHOGENESIS OF LIPOID NEPHROSIS: A DISORDER OF T-CELL FUNCTION
1974 Standout
Guillain‐Barré syndrome and Hodgkin's disease: Three cases with immunological studies
1977
Detection of Early Bladder Cancer by 5-Aminolevulinic Acid Induced Porphyrin Fluorescence
1996
Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy
1999 StandoutNobel
Use of Fluorescence In Situ Hybridization to Predict Response to Bacillus Calmette-Guérin Therapy for Bladder Cancer: Results of a Prospective Trial
2012
Cancer treatment and survivorship statistics, 2014
2014 Standout
Treatment of Superficial (T1) Tumours of the Bladder by Radical Radiotherapy
1986
Works of Michael P. Corder being referenced
Diffuse histiocytic lymphoma complicating chronic lymphocytic leukemia
1978
Superficial Bladder Cancer: Progression and Recurrence
1983
Phytohemagglutinin-induced Lymphocyte Transformation: The Relationship to Prognosis of Hodgkin’s Disease
1972
Delayed hypersensitivity in Hodgkin's disease
1972
Diffuse histiocytic lymphoma after histologic conversion: a poor prognostic variant.
1981
Successful therapy with methotrexate of a multicentric mixed lymphoma of the central nervous system
1976
A trial of razoxane (ICRF-159) in patients with prior therapy for Modgkin's Lymphoma
1984
Successful re-treatment with cis-dichlorodiammineplatinum(II) after apparent allergic reactions.
1979
Salvage therapy of aggressive non-Hodgkin's lymphoma with a combination of vinblastine, bleomycin, and cisplatin
1984
Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP)
1982
A decision-analysis methodology for consideration of morbidity factors in clinical decision-making
1984
Clinical usefulness and reproducibility of histologic subclassification of advanced diffuse histiocytic lymphoma
1979
A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A national bladder cancer collaborative group a study
1983
Radiotherapy plus razoxane for advanced limited extent carcinoma of the lung
1984